Skip to main content

Branded

  • Brenton Saunders tapped as new president, CEO of Forest Labs

    NEW YORK — The former CEO of Bausch + Lomb has been appointed president and CEO of Forest Labs, the drug maker said Tuesday.

  • Actavis, Warner Chilcott shareholders approve merger deal

    PARSIPPANY, N.J. — Shareholders of Actavis and Warner Chilcott have approved the merger of the two drug makers, the companies said Tuesday.

    The deal, whereby U.S.-based Actavis will acquire Ireland-based Warner Chilcott, is expected to close later this year.

  • FDA hikes GDUFA fees

    The Food and Drug Administration is raising the fees that generic drug companies will have to pay when filing for regulatory approval for new products or supplemental applications for existing products, the agency said last month.

  • Study: Almost one-third of adults are getting their flu shots after-hours

    LOS ANGELES — A study published Monday evening by the Annals of Family Medicine found that 30.5% of adults seeking vaccinations did so during the evening (17.4%), on the weekend (10.2%) or on a holiday (2.9%), such as Columbus Day or Veterans Day. The study also found that the patients who most likely received vaccinations during these times were younger (less than 65 years old), male, residing in urban areas and without chronic conditions — groups with historically lower vaccination rates. 

  • Biosimilars score a win

    The country's embryonic biosimilars industry scored a victory last month as the organization that runs the pension fund for California state employees announced its opposition to a state Senate bill provision that would impose special requirements on pharmacists who dispense follow-on biologics.

  • Celgene drug approved for metastatic pancreatic cancer

    SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Celgene for treating patients with pancreatic cancer that has spread to other parts of the body, the agency said Friday.

    The FDA announced the approval of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) for patients with late-stage forms of the disease. The drug is a chemotherapy treatment already approved for treating breast and lung cancers.

  • Otsuka to buy Astex for $886 million

    TOKYO — Japanese drug maker Otsuka Pharmaceutical Co. is buying U.S.-based Astex Pharmaceuticals for $886 million, Otsuka said Thursday.

    Astex, based in Dublin, Calif., uses a drug-discovery system known as fragment-based drug discovery, which enables rapid discovery and development of compounds for target proteins implicated in diseases and works by evaluating binding of target proteins with small molecules through 3D structural analysis. Astex developed and launched the chemotherapy drug Dacogen (decitabine), currently sold by Eisai.

  • ViiV Healthcare expands funding for HIV/AIDS organizations in South

    RESEARCH TRIANGLE PARK, N.C. — A joint venture founded by GlaxoSmithKline and Pfizer focused on treatments for HIV has expanded its support of community organizations in the South.

X
This ad will auto-close in 10 seconds